Accelerates Study Start-Up and Local Regulatory Approvals While Unlocking Access to Vast Diverse Patient Populations for Biotech and SMID Sponsors

GUILDFORD, UK, November 19 , 2025 — ERGOMED Clinical Research, an ERGOMED Group Company, continues to strengthen its global operations with the opening of new offices in Buenos Aires and the establishment of a strategic presence in both Brazil and Colombia. These developments enhance the company’s ability to deliver large-scale global programs with greater efficiency and cost-effectiveness, while enabling faster study start up, more seamless regulatory navigation, and broader access to diverse patient populations.

 

“Expanding into Latin America marks a significant milestone in our global growth strategy and provides us with enhanced abilities to run larger, longer term, and more complex trials across continents,” said Dave Selkirk, President of ERGOMED Clinical Research.  “We are better positioned than ever to meet the rising demand worldwide for oncology and rare disease trials.”

 

Greater Global Reach Provides Access to Ethnically Diverse Populations

With this expansion, ERGOMED Clinical Research strengthens its global presence and enhances access to diverse and rare patient populations across Latin America. Countries such as Brazil and Argentina offer large, ethnically varied populations and experienced research sites with strong expertise in oncology and rare diseases. This strategic growth enables sponsors to reach broader patient communities, improve trial accessibility, and accelerate recruitment in some of the world’s most dynamic healthcare markets.

 

Reinforced Global Capabilities to Support Complex, High-Value Trials

ERGOMED Clinical Research has strengthened its delivery capabilities to better serve the evolving needs of biotech and SMID sponsor partners, whether focused on patient-centric research or scaling to global trial execution. With enhanced infrastructure and operational capacity, the organization is now equipped to manage larger, longer-term, and more complex clinical trials across multiple continents. These advancements also bolster the company’s ability to support high-value programs in oncology, rare diseases, and other specialty or complex therapeutic areas.

 

Global Scale, Specialized Focus: Powering Next-Generation Clinical Trials

ERGOMED Clinical Research offers the distinctive advantage of combining the scale and resources of a global partner with the agility and specialized focus of a niche provider. This distinctive approach sets the organization apart from both smaller local organizations and large, one-size-fits-all CROs. Local teams manage the full spectrum of clinical trial execution, from submitting applications to regulatory authorities, to overseeing study start-up, on-site monitoring, drug safety, and project management, ensuring tailored support and deep regional expertise at every stage.

 

Strengthened Global Partner Positioning to Support Pipeline Globalization

ERGOMED Clinical Research has reinforced its position as a truly global CRO, backed by expanded regional depth and operational reach. This broadened footprint augments the company’s ability to serve as a strategic partner for biotech and pharmaceutical companies seeking to globalize their pipelines, offering the expertise and infrastructure needed to navigate complex, multi-regional trials with confidence.

 

About ERGOMED Group LLC

Founded in 1997, ERGOMED Group LLC has established itself as a trusted partner to biotech and pharmaceutical companies, delivering comprehensive support across all phases of clinical trials, post-approval pharmacovigilance, and medical information.

Internationally recognized Ergomed Group LLC is comprised of three affiliated companies:

  • ERGOMED Clinical Research: Stands as a global leader in oncology and rare disease drug development, drawing on 25 years of experience. The company delivers high-quality, innovative clinical research services and solutions, tailored to meet the demands of even the most complex clinical trials.
  • PrimeVigilance: Offers an industry-leading suite of specialist pharmacovigilance (PV) solutions.
  • ADAMAS Consulting: Provides mission-critical regulatory compliance and consulting services.

With a full-service approach and unwavering commitment to quality, Ergomed Group LLC accelerates development, ensures compliance, and optimizes commercial outcomes for both emerging and established life sciences companies.

For more information, visit www.ergomedgroup.com.